Scott Chappel, Ph.D., has been appointed chief scientific officer, iTeos Therapeutics SA. Dr. Chappel reports to chief executive officer Michel Detheux, Ph.D., and will be responsible for expanding the pipeline and leading the preclinical development of the company’s immuno-oncology programs that target the tumor microenvironment to improve the outcomes for cancer patients. “We are delighted that Scott has joined iTeos as CSO. He has been a leader in the life sciences sector for more than thr...